Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objectives of this study is to estimate the biological activity of combination chemotherapy and radiation versus radiation alone in patients with Hepato Cellular Carcinoma (HCC). The study hypothesizes is that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. The study hypothesizes that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. A biological response, or change in the tumor microenvironment (TME), is defined by reduced infiltration of intra-tumoral regulatory T cells (Tregs), a decrease in tumour-associated macrophages (TAMs) of the M2 phenotype, and an increase in immune cells such as effector CD8+ T-cells. An increased rate of biological response is therefore expected in participants receiving the combination of Durvalumab, Tremelimumab, and stereotactic body radiation therapy (SBRT), compared to those receiving SBRT alone. Additionally, biological response is hypothesized to correlate with pathological response. The study has been conducted within a WOO window of opportunity randomized clinical trial in order to obtain data in the quickest and safest manner. Patients undergoing surgery are very healthy by definition and will be able to tolerate treatment without any major complications, leading to adequate tissue samples before and after treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak wątroby bez przerzutów, pojedynczy guz lub niewielkie nowinki towarzyszące
- •Guz nie większy niż 12 cm
- •Planowana operacja chirurgiczna usunięcia guza
- •Wiek powyżej 18 lat
- •Dobra kondycja ogólna (ECOG 0-1)
- •Prawidłowa praca wątroby, nerek i szpiku kostnego
- •Waga powyżej 30 kg
- •Zgodę na udział w badaniu potwierdzoną podpisem
✗ Disqualifies
- •Poprzednia terapia raka wątroby (chemioterapia, operacja, radioterapia lub inne zabiegi)
- •Udział w innym badaniu klinicznym w ostatnich 4 tygodniach
- •Bieżące leczenie chemioterapią lub innymi lekami biologicznymi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Juravinski Hospital
Hamilton, Canada
London Health Sciences Centre
London, Canada
Trial contact
Pablo E Serrano, PhD, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.